- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00861094
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with radiation therapy may kill more tumor cells.
PURPOSE: This randomized phase II/III trial is studying radiation therapy and two different combination chemotherapy regimens to compare how well they work as first-line therapy in treating patients with esophageal cancer that cannot be removed by surgery.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
OBJECTIVES:
Primary
- To assess the feasibility of radiochemotherapy comprising oxaliplatin, fluorouracil, and leucovorin calcium (FOLFOX regimen) vs fluorouracil and cisplatin (Herskovic regimen) in patients with inoperable esophageal cancer. (Phase II)
- To assess the endoscopic complete response rate in patients treated with these regimens. (Phase II)
- To compare the event-free survival of patients treated with these regimens. (Phase III)
Secondary
- To assess the toxicity profile of these regimens using the NCI CTC v2.0 criteria. (Phase II)
- To compare the overall survival, endoscopic complete response rate, incidence of grade 3-4 toxicities, and time to treatment failure in patients treated with these regimens. (Phase III)
- To evaluate the quality of life of these patients using EORTC QLQ-C30 (version 3) and a validated disease-specific module EORTC QLQ-OES18. (Phase III)
OUTLINE: This is a multicenter study. Patients are stratified according to histological type (adenocarcinoma or adenosquamous carcinoma vs squamous cell carcinoma), pretreatment weight loss within the past 6 months (grade 1 [< 10%] vs grade 2 [≥ 10%]), ECOG performance status (0 vs 1 vs 2), and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I (modified FOLFOX 4 regimen): Patients undergo radiotherapy 5 days a week for 5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment with chemotherapy repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (Herskovic regimen): Patients undergo radiotherapy as in arm I. Patients also receive cisplatin IV continuously over 24 hours on day 1 and fluorouracil IV continuously over 96 hours on days 1-4 of weeks 1, 5, 8, and 11 in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, periodically during study therapy, and then every 6 months for 1 year and annually for 3 years after completion of study therapy.
After completion of study therapy, patients are followed at 4 weeks and then every 3-6 months until disease progression.
PROJECTED ACCRUAL: A total of 97 patients will be accrued for the phase II portion of the study. A total of 169 patients will be accrued for the phase III portion of the study.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Besancon, Francja, 25030
- CHR de Besancon - Hopital Saint-Jacques
-
Bordeaux, Francja, 33076
- Institut Bergonie
-
Bordeaux, Francja, 33075
- Hopital Saint André
-
Boulogne-Billancourt, Francja, F-92104
- Hôpital Ambroise Paré
-
Caen, Francja, 14076
- Centre Regional Francois Baclesse
-
Caen, Francja, 14052
- Polyclinique du Parc
-
Dijon, Francja, 21034
- Hôpital du Bocage
-
Dijon, Francja, 21079
- Centre de Lutte Contre le Cancer Georges-Francois Leclerc
-
Lille, Francja, 59020
- Centre Oscar Lambret
-
Limoges, Francja, 87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon, Francja, 69373
- Centre Léon Bérard
-
Marseille, Francja, 13385
- CHU de la Timone
-
Montpellier, Francja, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Nice, Francja, 06189
- Centre Antoine Lacassagne
-
Paris, Francja, 75015
- Hôpital Europeén Georges Pompidou
-
Paris, Francja, 75970
- Hôpital Tenon
-
Paris, Francja, 75475
- Hôpital Saint-Louis
-
Poitiers, Francja, 86021
- CHU Poitiers
-
Reims, Francja, 51092
- CHU - Robert Debre
-
Reims, Francja, 51056
- Institut Jean Godinot
-
Rennes, Francja, 35042
- Centre Eugene Marquis
-
Rouen, Francja, 76031
- Hôpital Charles Nicolle
-
Saint Brieuc, Francja, F-22015
- Clinique Armoricaine de Radiologie
-
Strasbourg, Francja, 67065
- Centre Paul Strauss
-
Toulouse, Francja, 31052
- Institut Claudius Regaud
-
Toulouse, Francja, 31078
- Clinique du Parc
-
Vandoeuvre-les-Nancy, Francja, 54511
- Centre Alexis Vautrin
-
Villejuif, Francja, F-94805
- Institut Gustave Roussy
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
DISEASE CHARACTERISTICS:
Histologically proven adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the esophagus
Locally advanced disease (any T, N0 or N1, M0 or M1a)
No metastatic disease, except for tumor involvement of the upper third of the esophagus or cervical esophageal tumor with regional nodes, or tumor involvement of the lower third of the esophagus with celiac nodes (M1a)
- Cervical primary tumor with positive supraclavicular or cervical lymph nodes (defined as N1) allowed
- No radiographic evidence of enlarged (≥ 1.5 cm) celiac lymph nodes by CT scan or echography
- No small cell or undifferentiated carcinoma of the esophagus
- No multiple carcinomas of the esophagus (i.e., > 1 esophageal tumor)
No cardia tumor (Siewert II) or gastric tumor extension to the esophagus (Siewert III)
- Esophageal tumor extension to the cardia (Siewert I) (center of the tumor lying > 1 cm-5 cm above gastroesophageal junction) allowed
- Inoperable disease OR surgery is contraindicated
- No tracheo-esophageal fistula or invasion of the tracheo-bronchial tree
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 3 months
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 10 g/dL (transfusion allowed)
- Creatinine < 15 mg/L
- Total bilirubin < 1.5 times upper limit of normal (ULN)
- ALT and AST < 2.5 times ULN
- Prothrombin time ≥ 60%
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Caloric intake sufficient (i.e., > 1,000 Kcal/m²/day) (orally or with gastrostomy)
- No weight loss > 20% normal body weight within the past 3 months
- No complete dysphagia
- No exclusive requirement for parenteral nutrition
No peripheral neuropathy > grade 1
- No sensitive peripheral neuropathy with functional impairment
- No auditory disorders
- No other prior malignancies except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix or stage I or II node-negative head and neck cancer that was curatively treated > 3 years ago
No myocardial infarction within the past 6 months
- Patients who have had a myocardial infarction > 6 months ago are eligible provided there is no transient ischemia by thallium myocardial scintigraphy and patient is able to undergo chemotherapy , as determined by a cardiologist
- No other serious illness or medical condition (e.g., symptomatic coronary disease, left ventricular failure, or uncontrolled infection)
- No stage II-IV arterial disease, according to the DE LERICHE and FONTAINE classification
- No geographical, social, or psychological circumstances preventing regular follow-up
PRIOR CONCURRENT THERAPY:
- No prior treatment for esophageal cancer (e.g., surgery, chemotherapy, or radiotherapy)
- No prior cervical, thoracic, or abdominal radiotherapy with field overlapping the proposed esophageal radiotherapy field
- More than 30 days since prior experimental drugs or participation in another clinical trial
- No other concurrent anticancer therapy
- No concurrent phenytoin or yellow fever vaccine
- No concurrent high-dose, long-term corticosteroids
- No concurrent calcium gluconate/magnesium sulfate infusions
- No concurrent hematopoietic growth factors
- No concurrent esophageal dilatation
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: FOLFOX and radiotherapy
Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
|
Inne nazwy:
|
|
Eksperymentalny: 5-FU / cisplatin and radiotherapy
5-FU (100mg/m2); Cisplatin (75mg/m2)
|
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Percentage of patients who complete the full study treatment (Phase II)
Ramy czasowe: 12 weeks
|
12 weeks
|
|
Endoscopic complete response rate (Phase II)
Ramy czasowe: 12 weeks
|
12 weeks
|
|
Progression-free survival (Phase III)
Ramy czasowe: Until progression
|
Until progression
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
|---|---|
|
Safety profile as assessed by NCI CTC v2.0 (Phase II)
Ramy czasowe: Total duration of the trial
|
Total duration of the trial
|
|
Overall survival (Phase III)
Ramy czasowe: Total duration of the trial
|
Total duration of the trial
|
|
Complete response rate (Phase III)
Ramy czasowe: Total duration of the trial
|
Total duration of the trial
|
|
Time to treatment failure (Phase III)
Ramy czasowe: Total duration of the trial
|
Total duration of the trial
|
|
Incidence of grade 3-4 toxicities (Phase III)
Ramy czasowe: Total duration of the trial
|
Total duration of the trial
|
|
Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)
Ramy czasowe: Total duration of the trial
|
Total duration of the trial
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Thierry Conroy, MD, Centre Alexis Vautrin
Publikacje i pomocne linki
Publikacje ogólne
- Winter A, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C. Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial. Qual Life Res. 2022 Sep 17. doi: 10.1007/s11136-022-03252-6. Online ahead of print.
- Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C. Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials. Qual Life Res. 2022 May;31(5):1359-1370. doi: 10.1007/s11136-021-03040-8. Epub 2021 Nov 24.
- Cuer B, Mollevi C, Anota A, Charton E, Juzyna B, Conroy T, Touraine C. Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17. BMC Med Res Methodol. 2020 Sep 3;20(1):223. doi: 10.1186/s12874-020-01104-w.
- Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Federation Francophone de Cancerologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Erratum In: Lancet Oncol. 2014 Dec;15(13):e587. Lancet Oncol. 2014 Dec;15(13):e587.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Nowotwory
- Nowotwory według lokalizacji
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby przewodu pokarmowego
- Nowotwory głowy i szyi
- Choroby przełyku
- Nowotwory przełyku
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Antymetabolity, przeciwnowotworowe
- Antymetabolity
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki ochronne
- Mikroelementy
- Witaminy
- Odtrutki
- Kompleks witamin B
- Hematynika
- Fluorouracyl
- Oksaliplatyna
- Leukoworyna
- Lewoleukoworyna
- Kwas foliowy
Inne numery identyfikacyjne badania
- CDR0000595050
- FRE-FNCLCC- ACCORD-17-0707
- EU-20848
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .